Latest news

• GSK files first application for triple COPD therapy

  protect its franchise with the launch of new two-drug combinations such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide).

• New drugs breathe life into GSK's respiratory business

  New asthma and COPD drugs such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide) added £243m ($319m) in the quarter, more than offsetting a 13% decline in Seretide

• GSK's triple COPD therapy tops Symbicort in phase III trial

  These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer

• GSK brings forward triple COPD therapy filing in US

  The company suffered declining respiratory sales through 2015 - although its performance improved in the first quarter of this year thanks to gathering momentum for two-drug combinations Relvar/Breo (vilanterol/fluticasone

• Respiratory return helps GSK to solid first quarter

  Relvar/Breo (vilanterol/fluticasone furoate), Anoro (vilanterol/umeclidinium bromide) and severe asthma debutante Nucala (mepolizumab).